Table 1. CAML Genotypes Shared by NTC/NCC Lineage Cancers & BC.
| Variant Microsatellite Loci in Individual Cancers | |||
|---|---|---|---|
| Cancer | Sample Population (n) | Significant Genotypes | Signature CAML Genotypes (FDR Corrected) |
| GBM | 252 | 178 | 48 |
| LGG | 136 | 145 | 42 |
| MEL | 149 | 157 | 68 |
| MB | 51 | 58 | 12 |
| BC | 656 | 242 | 52 |
| Signature CAML Genotypes Shared by Multiple Cancers | ||
|---|---|---|
| 3-Way Comparison of Cancers | Shared CAML | Significance (p-value) |
| MEL v. GBM v. LGG | 4 | 0.792 |
| MEL v. GBM v. MB | 1 | 1.000 |
| MEL v. BC v. GBM | 0 | 0.011* |
| LGG v. BC v. GBM | 0 | 0.023* |
| LGG v. MB v. MEL | 2 | 0.986 |
| LGG v. GBM v. MB | 2 | 1.000 |
| MB v. BC v. LGG | 0 | 0.037* |
| MB v. BC v. MEL | 1 | 0.175 |
| Signature CAML Genotypes Shared between Cancers | |
|---|---|
| Pair-Wise Comparison of Cancers | Number of Shared CAML |
| MEL v LGG | 23 |
| MEL v GBM | 7 |
| MEL v MB | 6 |
| MEL v BC | 3 |
| LGG v GBM | 6 |
| LGG v MB | 4 |
| LGG v BC | 2 |
| GBM v MB | 3 |
| GBM v BC | 7 |
| MB v BC | 1 |
Described for each disease cohort- Glioblastoma (GBM), lower grade glioma (LGG), melanoma (MEL), medulloblastoma (MB), and breast cancer (BC) are the number of samples (n) analyzed to identify significant microsatellite loci, and those loci with genotypes which form a signature of cancer-associated allelic pairs based on false discovery rate correction. Further described are the analyses of FDR corrected, signature loci shared between different cancers. Cancers compared in sets of 3 are described with a p-value (p < 0.05) and significance (*). Lastly, the number of shared signature CAML between any two cancers is described.